Fluoxymesterone
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-632-7753
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
| |
| Fluoxymesterone
| |
| Systematic (IUPAC) name | |
| 9-fluoro-11,17- dihydroxy-10,13,17- trimethyl-1,2,6,7,8,11,12,14,15,16- decahydrocyclopenta[a] phenanthren-3-one | |
| Identifiers | |
| CAS number | |
| ATC code | G03 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C20H29FO3 |
| Mol. mass | 336.441 g/mol |
| Pharmacokinetic data | |
| Bioavailability | 100% Oral |
| Metabolism | Hepatic |
| Half life | 9.5 hours |
| Excretion | urine |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
|
WikiDoc Resources for Fluoxymesterone | |
|
Articles | |
|---|---|
|
Most recent articles on Fluoxymesterone Most cited articles on Fluoxymesterone | |
|
Media | |
|
Powerpoint slides on Fluoxymesterone | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Fluoxymesterone at Clinical Trials.gov Trial results on Fluoxymesterone Clinical Trials on Fluoxymesterone at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Fluoxymesterone NICE Guidance on Fluoxymesterone
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Fluoxymesterone Discussion groups on Fluoxymesterone Patient Handouts on Fluoxymesterone Directions to Hospitals Treating Fluoxymesterone Risk calculators and risk factors for Fluoxymesterone
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Fluoxymesterone | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Business | |
|
Experimental / Informatics | |
Fluoxymesterone (Halotestin) is an androgenic steroid that is only useful to a small select group of athletes who seeks very specific goals. Athletes tend to use it to increase strength and aggression in the gym or in competitions such as strongman contests, fighting (like boxing) or MMA. The lack of estrogenic activity makes Halotestin perfect for pre-fight usage – as weigh-ins would not be effected by water retention. Even in such an events, Fluoxymesterone usage is usually limited to mere few weeks rather than cycled like real steroids for months.
Fluoxymesterone (Halotestin) has poor binding to the AR. Studies have shown the effects to be mostly non-AR mediated. However, it is considered a very toxic oral drug, and a poor choice in most bodybuilding/steroid use applications.
The half life of Fluoxymesterone (Halotestin) is commonly misunderstood. The rumored belief is that 30-90 minutes is the half-life but this rumor is false, the half life of Fluoxymesterone is about 9.5 hours.
Further reading
Daniels, R. C. (February 1, 2003). The Anabolic Steroid Handbook. Richard C Daniels, 80. ISBN 0-9548227-0-6.
External links
Anabolic steroids (A14) (trademark names in brackets) | |
|---|---|
| Androstan (carbon 19 present) | Androstadienone • Boldenone undecylenate (Equipoise) • 4-Chlordehydromethyltestosterone (Turinabol) • Clostebol • Desoxymethyltestosterone (Madol) • DHEA • DHT • Drostanolone (Masteron) • Fluoxymesterone (Halotestin) • Furazabol (Miotolan) • Methandrostenolone (Dianabol) • Methenolone • Mesterolone (Proviron) • Methenolone enanthate (Primobolan) • Mestanolone • Norethandrolone • Oxandrolone (Anavar) • Oxymetholone (Anadrol) • Oxymetholone (Anadrol-50) • Quinbolone (Anabolicum Vister) • Stanozolol (Winstrol) • Testosterone |
| Estren (carbon 19 absent) | Ethylestrenol • Mibolerone (Cheque Drops) • Nandrolone (Deca Durabolin) • Norbolethone (Genabol) • Oxabolone cipionate • Tetrahydrogestrinone (The Clear) • Trenbolone (Fina) |
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
